구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist) Merck Sharp & Dohme LLC·Carcinoma, Non-Small-Cell Lung 45 trials·t½ 34 h |
|---|---|
Overview Program | Neurokinin-1 receptor antagonist |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptor |
MoA Biomarker | biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision m |
PK/PD Half-life | 34 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.. Motion sickness affects millions of people with common symptoms, including nausea and vomiting. Medications used for management of motion sickness since 1870 predominately have anticholinergics and antihistamines properties. For the past 40 years, there have been no advances in medication options for motion sickness until … |
Clinical Safety signal | Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.. Motion sickness affects millions of people with common symptoms, including nausea and vomiting. Medications used for management of motion sickness since 1870 predominately have anticholinergics and antihistamines properties. For the past 40 years, there have been no advances in medication options for motion sickness until … |
Clinical Result source | ClinicalTrials.gov NCT00601172 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00601172 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist) Merck Sharp & Dohme LLC·Carcinoma, Non-Small-Cell Lung 45 trials·t½ 34 h |
|---|---|
Overview Program | Neurokinin-1 receptor antagonist |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targets beyond conventional monoaminergic approaches, focusing on sodium channels, Neuropeptide Y (NPY), Neurokinin 1 (NK1) receptors, P2 × 7 purinergic receptors, Sigma-1 receptor |
MoA Biomarker | biomarkers for patient stratification will be critical in the hitherto elusive goal of developing precision m |
PK/PD Half-life | 34 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.. Motion sickness affects millions of people with common symptoms, including nausea and vomiting. Medications used for management of motion sickness since 1870 predominately have anticholinergics and antihistamines properties. For the past 40 years, there have been no advances in medication options for motion sickness until … |
Clinical Safety signal | Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.. Motion sickness affects millions of people with common symptoms, including nausea and vomiting. Medications used for management of motion sickness since 1870 predominately have anticholinergics and antihistamines properties. For the past 40 years, there have been no advances in medication options for motion sickness until … |
Clinical Result source | ClinicalTrials.gov NCT00601172 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT00601172 |
추천 비교
추천 비교